Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
This review says cannabidiol (CBD) is a non‑psychoactive cannabis compound that has antioxidant and anti‑inflammatory actions in lab and some clinical studies. CBD can act directly to neutralize reactive molecules and indirectly by changing cell signals and antioxidant enzymes. Experiments in cells and animals show CBD lowers markers of oxidative…
This review collected human studies on how cannabidiol (CBD) is absorbed, distributed, and cleared. From 792 records, 24 studies reported pharmacokinetic (PK) data. Results varied by how CBD was given and by formulation. For example, smoking produced faster and higher blood levels than oral or oromucosal routes. The authors concluded…
This was a small, randomized, double-blind, placebo-controlled 13-week pilot trial of two nonpsychoactive cannabis-related compounds (cannabidiol, CBD, and tetrahydrocannabivarin, THCV) in 62 people with type 2 diabetes who were not using insulin. Participants were assigned to CBD, THCV, two CBD/THCV combination doses, or placebo. Compared with placebo, THCV lowered fasting…
THCV is a cannabis compound that does not cause the “high” linked to THC. In animal studies it lowered appetite, increased feelings of fullness, and raised energy use, and some small studies in people with type 2 diabetes found lower fasting blood sugar versus placebo. Researchers say these findings make…
This study gave the same oral dose of cannabidiol (CBD) to male and female rats using three product types: isolate, broad‑spectrum, and full‑spectrum. When CBD was given as a full‑spectrum product that included about 0.2% THC, CBD blood levels were higher than with isolate or broad‑spectrum. Lab tests showed THC…
This editorial reviews evidence that compounds in marijuana, especially THC and CBD, might protect brain cells and affect symptoms in diseases like Alzheimer's, Parkinson's, Huntington's, and ALS. Lab and animal studies have found anti-inflammatory and antioxidant effects and signs of neuron protection. Human clinical studies are few but show some…
A placebo-controlled study of 44 adults (average age 51.8) tested daily mucoadhesive oral strips containing THCV and CBD for 90 days. Both the lower dose (8 mg THCV/10 mg CBD) and the higher dose (16 mg THCV/20 mg CBD) were associated with statistically significant weight loss versus placebo, and the…
